We are live on ! Find out more
DMAC icon

DiaMedica Therapeutics
DMAC

33 hedge funds and large institutions have $28.4M invested in DiaMedica Therapeutics in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 2

333% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 3

43% more funds holding

Funds holding: 23 → 33 (+10)

35% more capital invested

Capital invested by funds: $21M → $28.4M (+$7.36M)

14.33% more ownership

Funds ownership: 21.46% → 35.8% (+14%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
33
Holders Change
+10
Holders Change %
+43.48%
% of All Funds
0.67%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
13
Increased
12
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.23M
2
CA
Corriente Advisors
Texas
+$2.8M
3
SCM
Stonepine Capital Management
Oregon
+$2.53M
4
IC
Ikarian Capital
Texas
+$2.2M
5
MS
Maven Securities
Jersey
+$1.9M

Top Sellers

Rank Fund Capital Flow
1
William Blair & Company
William Blair & Company
Illinois
-$69K
2
Renaissance Technologies
Renaissance Technologies
New York
-$46K
3
UBS Group
UBS Group
Switzerland
-$4K
4
BlackRock
BlackRock
New York
-$3.89K
5
Bank of America
Bank of America
North Carolina
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Stonepine Capital Management
Oregon
$4.86M +$2.53M +478,040 +72%
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$3.39M +$4.23M +800,000 New
NCM
3
Nantahala Capital Management
Connecticut
$3.21M +$32.8K +6,193 +0.8%
CA
4
Corriente Advisors
Texas
$3.1M +$2.8M +528,752 +263%
GPCM
5
Granite Point Capital Management
Massachusetts
$2.74M +$897K +169,625 +36%
MHP
6
Manatuck Hill Partners
Connecticut
$2.42M +$1.17M +220,400 +63%
IC
7
Ikarian Capital
Texas
$1.76M +$2.2M +415,000 New
MS
8
Maven Securities
Jersey
$1.47M +$1.9M +359,285 New
Vanguard Group
9
Vanguard Group
Pennsylvania
$1.45M +$529K +100,027 +41%
CH
10
CVI Holdings
Delaware
$1.17M +$1.46M +276,176 New
DCM
11
DAFNA Capital Management
California
$664K +$828K +156,529 New
Northern Trust
12
Northern Trust
Illinois
$495K +$111K +20,896 +22%
Renaissance Technologies
13
Renaissance Technologies
New York
$407K -$46K -8,700 -8%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$265K +$33.1K +6,250 +11%
BFM
15
Boothbay Fund Management
New York
$197K +$246K +46,562 New
BlackRock
16
BlackRock
New York
$185K -$3.89K -735 -2%
WVP
17
Worth Venture Partners
New Jersey
$182K +$227K +42,887 New
Qube Research & Technologies (QRT)
18
Qube Research & Technologies (QRT)
United Kingdom
$132K +$165K +31,234 New
MCM
19
Moore Capital Management
New York
$106K +$132K +25,000 New
Bank of New York Mellon
20
Bank of New York Mellon
New York
$57K – – –
Morgan Stanley
21
Morgan Stanley
New York
$38K +$17.5K +3,300 +57%
FDCDDQ
22
Federation des caisses Desjardins du Quebec
Quebec, Canada
$24.6K – – –
US Bancorp
23
US Bancorp
Minnesota
$18K +$22.9K +4,335 New
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$11K +$1.5K +284 +12%
APA
25
American Portfolios Advisors
New York
$10.6K – – –
1
2

DMAC Hedge Fund Activity: Q3 2020 in Review

33 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q3 2020, worth a combined $28.4M — up 35% from $21M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new DMAC positions and 3 closed out — a net gain of 10 holders — while 12 added to existing stakes and 2 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $4.23M. The largest seller was William Blair & Company, exiting entirely with an estimated $69K sold.

  • 33 institutional investors held DiaMedica Therapeutics (DMAC) as of Q3 2020, up from 23 in Q2 2020.
  • Funds reported $28.4M of DiaMedica Therapeutics stock for Q3 2020, up 35% quarter-over-quarter.
  • 13 funds opened new DiaMedica Therapeutics positions in Q3 2020 and 3 closed out, a net change of +10 holders.
  • The largest DiaMedica Therapeutics buyer in Q3 2020 was Point72 Asset Management, an estimated $4.23M added.
  • The largest DiaMedica Therapeutics seller in Q3 2020 was William Blair & Company, an estimated $69K sold.

Based on aggregated 13F filings for Q3 2020.